Oncology & Cancer

Predicting cancer's next move

Research led by Broad senior associate member Levi Garraway and published this week in Nature offers a new approach to studying drug resistance in cancer. The approach helped them identify which biological pathways could ...

Oncology & Cancer

RNA regulator of melanoma could be a new target for cancer therapy

Melanoma is the most deadly form of skin cancer, estimated by the National Cancer Institute to afflict more than 70,000 people in the United States annually and the incidence rate continues to rise. In a study published online ...

Oncology & Cancer

The role of fibronectin in BRAF-mutant thyroid cancer treatment

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, Ph.D., could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene—a mutation also ...

Oncology & Cancer

A Braf kinase-inactive mutant induces lung adenocarcinoma

The initiating oncogenic event in almost half of human lung adenocarcinomas is still unknown, complicating the development of selective targeted therapies. Yet these tumours harbour a number of alterations without obvious ...

Oncology & Cancer

Cutting off all points of escape for melanoma cells

Despite the success of recent approved therapeutics to treat advanced melanoma, metastatic cancer cells inevitably evolve resistance to drugs. In the journal Cell Reports, a team of researchers based at The Wistar Institute, ...

page 8 from 12